Prof. Junxin Wu 吴君心
Chief Physician, Professor
Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision radiotherapy and comprehensive treatment for brain tumors, breast cancer, lymphoma, and abdominal malignancies.
Dr. Wu holds an MD from Peking Union Medical College (2003) and completed postdoctoral work at Karolinska Institutet, with visiting scholar experience at Memorial Sloan Kettering Cancer Center. As Chief of Radiotherapy at Fujian Cancer Hospital, Dr. Wu specializes in IMRT, image-guided radiotherapy, VMAT, and TOMO for abdominal, breast, lymphoma, and neuro-oncology cases.
Professional roles
- Chair, Radiation Oncology Branch, Fujian Medical Association
- Chair, Radiation Oncology Committee, Fujian Anti-Cancer Association (3rd Term)
- Vice Chair, Translational Medicine Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Tumor Radiotherapy Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Wu Junxin). Papers usually list the name as Junxin Wu or Wu J.
Selected publications
68 papers on PubMed matched by name and affiliation; 46 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Development and validation of a novel nomogram integrating visceral-to-subcutaneous fat ratio and neutrophil-percentage-to-albumin ratio for overall survival in locally advanced rectal cancer undergoing neoadjuvant radiotherapy. PubMed 42755654
- BMC Cancer, 2026 (senior author): Leveraging data-driven risk-adapted surveillance strategies after disease progression in locally advanced rectal cancer. PubMed 42393631
- Cell Death Dis, 2026 (senior author): EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. PubMed 42336814
- Front Oncol, 2026 (senior author): Correction: Risk stratification for adjuvant radiotherapy in pathologic T3N0 rectal cancer using a DeepSurv-based survival model. PubMed 42370127
- Front Oncol, 2026 (senior author): Risk stratification for adjuvant radiotherapy in pathologic T3N0 rectal cancer using a DeepSurv-based survival model. PubMed 42394705
- J Appl Clin Med Phys, 2026 (senior author): Predictive value of primary gross tumor volume measured by MRI in response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. PubMed 42142395
- Microbiol Spectr, 2026 (senior author): HERV6196 as an enhancer with oncogenic potential in rectal cancer. PubMed 41358726
- Sci Rep, 2025 (senior author): Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses. PubMed 41028204
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion